Northwire Canada EditionThursday, October 15, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4% GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4%
Financings Routine −

Lophos Holdings Inc. Announces Partial Revocation of Cease Trade Order, Proposed Consolidation and Financing

Regulatory Survival Financing Keeps Halted Psychedelic Micro-Cap Afloat Amid CSDL Loss

By The Northwire Desk — AI Analysis Jul 01, 2026 · 10:20 MESC · 0.01 Lophos Holdings Inc.
Executive Summary
  • Lophos Holdings Inc. received a Partial Revocation Order from the BCSC, permitting a $530,000 private placement despite an existing failure-to-file cease trade order (FFCTO).
  • The financing consists of up to 17,666,666 units priced at $0.03 per unit, each containing one common share and one warrant exercisable at $0.05 for 36 months.
  • A 1-for-3 share consolidation will precede the financing, reducing the outstanding share count to approximately 29,328,224 post-consolidation shares.
  • Proceeds are strictly allocated to updating continuous disclosure records, paying regulatory fees and penalties, covering financing costs, and funding basic operating expenses.
  • The company previously lost its site-specific Controlled Substances Dealer's Licence (CSDL) in June after disposing of its Napanee, Ontario facility, effectively halting direct regulated operations.
Material Impact
  • The financing is a compliance-driven survival measure rather than a growth catalyst. Raising $530,000 to clear regulatory backlogs and maintain corporate existence highlights severe liquidity constraints.
  • The 1-for-3 consolidation and warrant issuance are standard micro-cap tactics but introduce immediate dilution for existing shareholders.
  • Loss of the CSDL and the ongoing FFCTO mean the company cannot trade its stock or operate its core licensed activities until further regulatory and operational hurdles are cleared.
  • The news does not alter the fundamental risk profile; it merely extends the company's runway to address administrative and regulatory deficiencies.
MESC · Price
Company Overview
  • Lophos Holdings Inc. is a Canadian entity focused on the research and development of controlled substances, including MDMA, ketamine, LSD, DMT, mescaline, psilocin, and psilocybin.
  • The company previously operated a 10,000-square-foot facility in Napanee, Ontario, under a site-specific CSDL.
  • Following the disposition of the facility via mortgage enforcement proceedings, the CSDL was lost. Management is now pivoting to a partnership-based model, leveraging third-party license holders and contract research organizations to continue its pipeline without heavy infrastructure expenditures.
  • The company is currently under a failure-to-file cease trade order, halting all public trading.
Read the original news release →

More from Lophos Holdings Inc.

Jun 11, 2026 · 21:08

Dormant Psychedelic Developer Grapples with License Loss and Ongoing Trading Halt

Regulatory